The patents on glucocorticosteroids and selected new therapies for the management of asthma in children

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 1, 2011, Pages 57-65

  Eusebio, Makandjou Ola ^a   Grzelewski, Tomasz ^b   Pietruczuk, Miroslawa ^a   Lewandowska, Beata ^b   Stelmach, Iwona ^b  

^a N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Asthma; Children; Glucocorticosteroids; Patents

Indexed keywords

1,3 DIHYDRO IMIDAZO[4,5 C]QUINOLIN 2 ONE; 4 (2 FLUOROPHENYL) 6 METHVI 2 (PIPERAZIN 1 VDTHIENO[2,3 DIPYRIMIDINE)]; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE DEAMINASE; ANDROSTENEDIOL; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; EOTAXIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; PEGADEMASE; PRASTERONE; PRASTERONE SULFATE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ASTHMA; CAREGIVER; CHILD; CHILDHOOD DISEASE; DRUG SELF ADMINISTRATION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; PARENT; PATENT; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW;

ASTHMA; CHEMOKINE CCL11; CHILD; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PATENTS AS TOPIC;

EID: 79551627266     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311794474865     Document Type: Review

References (78)

1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2009. Available at: http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=1561 [Aceesed on: February 5, 2010].
2. Walsh GM. Novel therapies for asthma-advances and problems. Curr Pharm Des 2005; 11: 3027-3038.
3. Belvisi MG, Hele DJ, Birrell MA. New advances and potential therapies for the treatment of asthma. BioDrugs 2004; 18 (4): 211-223.
4. Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immnol 2003; 111(Suppl1): S37-S42.
5. Freishtat RJ, Nagaraju K, Jusko W, Hoffman EP. Glucocorticoid efficacy in asthma: Is improved tissue remodeling upstream of antiinflammation. J Investig Med 2010; 58(1): 19-22.
6. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry crosssectional surveys. Lancet 2006; 368: 733-743.
7. Corburn J, Osleeb J, Porter M. Urban asthma and the neighbourhood environment in New York City. Health Place 2006; 12 (2): 167-179.
8. Williams DR, Sternthal M, Wright RJ. Social determinants: Taking the social context of asthma seriously. Pediatrics 2009; 123(3): S174-S184.
9. Fisher GB, Camargos AM. Pediatric asthma management in developing countries. Paediatr Respir Rev 2002; 3: 285-291.
10. Keirns CC. Asthma mitigation strategies professional, charitable, and community coalitions. Am J Prev Med 2009; 37(6S1): S244-S250.
11. Adcock IM, Ito K. Steroid resistance in asthma. Curr Opin Pharmacol 2004; 4: 257-262.
12. Fitzpatrick AM, Kir T, Naeher LP, Fuhrman SC, Hahn K, Teague WG. Asthma prescription refill frequencies. J Pediatr Nurs 2009; 24(2): 81-89.
13. Baena-Cagnani CE, Passalacqua G, Gómez M, Zernotti ME, Canonica GW. New perspectives in the treatment of allergic rhinitis and asthma in children. Curr Opin Allergy Clin Immunol 2007; 7(2): 201-206.
14. Ward WK, Hansen JC, Massoud RG, Engle JM, Takeno MM, Hauch KD. Controlled release of dexamethasone from subcutaneously- implanted biosensors in pigs: Localized anti-inflammatory benefit without systemic effect. J Biomed Mater Res 2010; 94: 280-287.
15. Barnes PJ, Adcock IM. How corticosteroids work in asthma? Ann Intern Med 2003; 139: 359-370.
16. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-kB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009; 121: 1-13.
17. Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 2000; 13(3): 115-126.
18. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G. Glucocorticoids and inflammation revisited: The state of the art. Neuroimmunomodulation 2002-2003; 10(5): 247-260.
19. Grabstein K, Dower S, Gillis S, Urdal D, Larsen A. Expression of interleukin 2, interferon-gamma, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol 1986; 136: 4503-4508.
20. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25(3): 451-468.
21. Russcher H, Dalm VA, de Jong FH, Brinkmann AO, Hofland LJ, Lamberts SW, et al. Associations between promoter usage and alternative splicing of the glucocorticoid receptor gene. J Mol Endocrinol 2007; 38: 91-98.
22. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154: 771-782.
23. Vachier I, Chiappara G, Vignola AM, Gagliardo R, Altieri E, Terouanne B, et al. Glucocorticoid receptors in bronchial epithelial cells in asthma. Am J Respir Crit Care Med 1998; 158: 963-970.
24. Yudt MR, Cidlowski JA. Molecular identification and characterization of alpha and beta forms of the glucocorticoid receptor. Mol Endocrinol 2001; 15(7): 1093-1103.
25. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75(1): 1-12.
26. Pujolsa L, Mullol J, Picado C. Pujolsa L, Mullol J, Picado C. Glucocorticoid receptor in human respiratory epithelial cells. Neuroimmunomodulation 2009; 16(5): 290-299.
27. Derijk RH, Schaaf M, Stam FJ, De Jong IEM, Swaab DF, Ravid R, et al. Very low levels of the glucocorticoid receptor b isoform in the human hippocampus as shown by Taqman RT-PCR and immunocytochemistry. Mol Brain Res 2003; 116: 17-26.
28. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147: 3490-3495.
29. Saleh D, Ernst P, Lim S, Barnes P J, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: Effect of inhaled glucocorticoid. FASEB J 1998; 12: 929-937.
30. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134(2): 394-401.
31. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative b isoform: A mechanism for the generation of glucocorticoid resistance Proc Natl Acad Sci USA 2001; 98: 6865-6870.
32. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: An important mechanism if inflammatory lung diseases. COPD 2005; 2(4): 445-455.
33. Bowler RP. Oxidative stress in the pathogenesis of asthma. Curr Allergy Asthma Rep 2004; 4(2): 116-122.
34. Prince, G. A., Hemming, V. G. A method for treating infectious respiratory diseases. WO92019244 (1992) & US5290540 (1994).
35. Hofmann, T. Method for treatment of COPD and other pulmonary diseases US20100092397 (2010).
36. Blackburn, M. R., Horak, I., Sapra, P. Use of adenosine deaminase for treating pulmonary disease. US20080159964 (2008).
37. Robinson, C. B., Ball, H.A. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis. WO2005099720 (2005) & US20090317477 (2009).
38. Robinson, C. B., Ball, H.A. Combination of dehydro-epiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease. WO2005011603 (2005).
39. Vaughan, T.J., Wilton, A.J., Smith, S., Main, S.H. Human antibodies against eotaxin and their use. WO2001066754 (2001).
40. Cooper, M., Ian, F., Christopher, S. Crystalline forms of 4-(2- Fluorophenyl)-6-Methyl-2-(Piperazin-1-YL) thieno (2, 3-D) pyrimidine. WO2008051282 (2008).
41. Garcia-Echeverria, C., Stauffer, F., Furet, P.1, 3-Dihydro-imidazo [4, 5-C] quinolin-2-ones as lipid kinase inhibitors. US20080194579 (2008) & US20100056558 (2010).
42. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
43. Nyce, J.W. Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone. US6087351 (2000).
44. Forsythe P, Ennis M. Adenosine, mast cells and asthma. Inflamm Res 1999; 48(6): 301-307.
45. Brown RA, Spina D, Page CP. Adenosine receptors and astma. Br J Pharmacol 2008; 153 (Suppl 1): S446-S456.
46. Leff A. Pathogenesis of asthma, neurophysiology and pharmacology of bronchospam. Chest 1982; 81(2): 224-229.
47. Feoktistov I, Biaggioni I. Role of adenosine in asthma. Drug Dev Res 1996; 39: 333-336.
48. Eckle T, Grenz A, Laucher S, Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. Clin Invest 2008; 118: 3301-3315.
49. Kellems, R. E., Datta, S. K., Blackburn, M. R. Adenosine deaminase deficient transgenic mice and methods for the use thereof. US6207876 (2001).
50. Nyce, J.W. Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone. US6087351 (2000).
51. Choi IS, Cui Y, Koh YA, Lee HC, Cho YB, Won YH. Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics. Korean J Intern Med 2008; 23(4): 176-181.
52. Fozard JR. The case for a role for adenosine in asthma: Almost convincing? Curr Opin Pharmacol 2003; 3: 264-269.
53. Polosa R. Adenosine receptor subtypes: Their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J 2002; 20: 488-496.
54. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004; 3 (2): 171-187.
55. Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19(4): 148-153.
56. Buceta MO, Dominguez E, Castro M, Brea J, Alvarez D, Barcala J, et al. A new chemical tool (C0036E08) supports the role of adenosine A2B receptors in mediating human mast cell activation. Biochem Pharmacol 2008; 76: 912-921.
57. Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: A Ca21-activated K1-channel opener. Am J Physiol Lung Cell Mol Physiol 1998; 274: 186-195.
58. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, et al. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids 2003; 68(1): 73-83.
59. Bednarek-Tupikowska G, Gosk I, Szuba A, Bohdanowicz-Pawlak A, Kosowska B, Bidzińska B, et al. Influence of dehydroepiandrosterone on platelet aggregation, superoxide dismutase activity and serum lipid peroxide concentrations in rabbits with induced hypercholesterolemia. Med Sci Monit 2000; 6(1): 40-45.
60. Wilson CN, Nadeem A, Spina D, Brown R, Page CP, Mustafa SJ. Adenosine receptors and asthma. Handb Exp Pharmacol 2009; (193): 329-362.
61. Rorke S, Holgate ST. Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am J Respir Med 2002; 1(2): 99-105.
62. Nyce, J. W. Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof. US5527789 (1996).
63. Stanley TP. Cytokines in inflammatory diseases: Role and therapeutic targets in acute respiratory distress syndrome. Expert Opin Ther Targets 1998; 2: 1-16.
64. Walsh GM. Targeting airway inflammation: Novel therapies for the treatment of asthma. Curr Med Chem 2006; 13: 3105-3111.
65. Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 2009; 19(1): 39-58.
66. Anderskewitz R, Bauer R, Bodenbach G, Gester D, Gramlich B, Morschhäuser G, et al. Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators. Bioorg Med Chem Lett 2005; 15(3): 669-673.
67. Gong L, Wilhelm RS. CCR3 antagonists: A survey of the patent literature. Expert Opin Ther Pat 2009; 19(8): 1109-1132.
68. Budhu, R. J., Holson, E., Hale, J. J., Lynch, C., Maccoss, M., Berk, S.C., Mills, S.G., Willoughby, C.A. Pyrrolidine and piperidine modulators of chemokine receptor activity. US6166037 (2000).
69. Bellucci F, Cucchi P, Catalani C, Giuliani S, Meini S, Maggi CA. Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts. Br J Pharmacol 2009; 158(8): 1996-2004.
70. Iwona S, Tomasz G. Antileukotriene treatment in children with asthma-new patents. Recent Pat Inflamm Allergy Drug Discov 2008; 2(3): 202-211.
71. Zimmermann GR, Avery W, Finelli AL, Farwell M, Fraser CC, Borisy AA. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther 2009; 11(1): R12.
72. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117: 522-543.
73. Schwarz MK, Wells TN. New therapeutics that modulate chemokines networks. Nat Rev Drug Discov 2002; 1(5): 347-358.
74. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 2009; 260(1): 33-38.
75. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 2006; 97: 1184-1190.
76. Bowler RP. Oxidative stress in the pathogenesis of asthma. Curr Allergy Asthma Rep 2004; 4(2): 116-122.
77. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase. Activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
78. June, C.H. Methods for modulating T cell responses by manipulating intracellular signal transduction. US6632789 (2003).